An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2017
At a glance
- Drugs GSK 3277511 (Primary)
- Indications Respiratory tract disorders
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 06 Apr 2017 Status changed from active, no longer recruiting to completed.
- 03 Apr 2017 Planned End Date changed from 1 Mar 2017 to 3 Apr 2017.
- 03 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 3 Apr 2017.